How Analysts Feel About Affimed N.V. (NASDAQ:AFMD) After Decrease in Sellers?

June 17, 2018 - By Migdalia James

The stock of Affimed N.V. (NASDAQ:AFMD) registered a decrease of 24.35% in short interest. AFMD’s total short interest was 369,800 shares in June as published by FINRA. Its down 24.35% from 488,800 shares, reported previously. With 252,600 shares average volume, it will take short sellers 2 days to cover their AFMD’s short positions. The short interest to Affimed N.V.’s float is 1.46%.

The stock decreased 15.31% or $0.375 during the last trading session, reaching $2.075. About 2.81M shares traded or 533.01% up from the average. Affimed N.V. (NASDAQ:AFMD) has declined 6.38% since June 17, 2017 and is downtrending. It has underperformed by 18.95% the S&P500.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $129.46 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

More notable recent Affimed N.V. (NASDAQ:AFMD) news were published by: which released: “30 Stocks Moving In Friday’s Mid-Day Session” on June 15, 2018, also with their article: “31 Stocks Moving In Thursday’s Mid-Day Session” published on June 14, 2018, published: “Mid-Morning Market Update: Markets Open Lower; Adobe Beats Q2 Expectations” on June 15, 2018. More interesting news about Affimed N.V. (NASDAQ:AFMD) were released by: and their article: “Mid-Afternoon Market Update: Crude Oil Down Over 3%; Canada Goose Shares Gain Following Strong Q4 Results” published on June 15, 2018 as well as‘s news article titled: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” with publication date: June 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.